title: Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study.
abstract: OBJECTIVE
  A prospective multicenter validation of the ability of 1H magnetic resonance spectroscopic imaging (MRSI) to distinguish cancer from noncancer tissues throughout the prostate with histopathology of the resected organ as the standard of reference.
  
  
  METHODS
  Institutional review board approval was obtained for all centers and all participating patients and volunteers provided written informed consent. Ninety-nine patients and 10 age-matched volunteers from 8 participating centers underwent magnetic resonance imaging and 3-dimensional MRSI with an endorectal coil at 1.5 T. Selected MRSI voxels were assigned to the peripheral zone (PZ), the central gland (CG), the periurethral area, and cancer tissue. Signal ratios of choline + creatine to citrate (CC/C) in spectra of these voxels were automatically calculated. Receiver operating characteristic curves were constructed to assess the accuracy by which this ratio can discriminate cancer from noncancer tissue.
  
  
  RESULTS
  A total of 70% of voxels in noncancer tissue and 90% of voxels in cancer tissue passed the quality check of the automatically fitted spectra. The median CC/C was significantly different between any noncancer and cancer tissue (P < 0.0001), but not between the different contributing centers. CC/C increased with cancer focus size (P =0.0008) and certainty of voxel mapping to histopathologic cancer site (P 0.0001). The area under the receiver operating characteristic curve for discriminating voxels of cancer tissue from noncancer tissue was 0.88 (confidence interval: 0.84-0.92) in the PZ and 0.76 (confidence interval: 0.71- 0.81) in the CG.
authors.affiliation: Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
authors.forename: Tom W J
authors.initials: TW
authors.lastname: Scheenen
authors.forename: Jurgen
authors.initials: J
authors.lastname: Fütterer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Weiland
authors.forename: Paul
authors.initials: P
authors.lastname: van Hecke
authors.forename: Marc
authors.initials: M
authors.lastname: Lemort
authors.forename: Christian
authors.initials: C
authors.lastname: Zechmann
authors.forename: Heinz-Peter
authors.initials: HP
authors.lastname: Schlemmer
authors.forename: Dale
authors.initials: D
authors.lastname: Broome
authors.forename: Geert
authors.initials: G
authors.lastname: Villeirs
authors.forename: Jianping
authors.initials: J
authors.lastname: Lu
authors.forename: Jelle
authors.initials: J
authors.lastname: Barentsz
authors.forename: Stefan
authors.initials: S
authors.lastname: Roell
authors.forename: Arend
authors.initials: A
authors.lastname: Heerschap
mesh_terms: D000368:Aged; D016001:Confidence Intervals; D006305:Health Status Indicators; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000295:instrumentation* / Q000379:methods; D016014:Linear Models; D009682:Magnetic Resonance Spectroscopy / Q000295:instrumentation / Q000379:methods / Q000592:standards*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology* / Q000601:surgery; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D011786:Quality Control; D012372:ROC Curve; D012307:Risk Factors; D018709:Statistics, Nonparametric
chemical_list: D017430:Prostate-Specific Antigen